EV-based Liquid Biopsy Market worth $349.19 Million by 2031 - Exclusive Report by InsightAce Analytic

News provided by

Jul 25, 2023, 10:45 ET

JERSEY CITY, N.J., July 25, 2023 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global EV-based Liquid Biopsy Market Size, Share & Trends Analysis Report By Offering (Kits & Assays, Instruments, Services), Workflow (Sample Preparation, Sequencing, Data Analysis), Technology (Isolation Technologies and Detection Technologies), Sample Type (Blood (Plasma/Serum), Urine, Saliva, Other Biofluids (CF - Cerebrospinal fluid), Cell Culture), End User (Academic & Research Institutions, Clinical Laboratories, Pharmaceutical & Biotechnology Companies) Market Outlook And Industry Analysis 2031"

According to the latest research by InsightAce Analytic, the global EV-based Liquid Biopsy Market size is valued at US$ 74.61 Million in 2022, and it is expected to reach US$ 349.19 Million in 2031, recording a promising CAGR of 18.9% during the forecast period of 2023-2031.

Extracellular Vesicles (EVs) are released by every body cell, which is a snapshot of cellular biological activity. They can be in biofluids such as blood and provide the best way to detect and prevent non-invasive diseases, including cancer. EV-based liquid biopsy holds great promise for cancer diagnosis, prognosis and clinical monitoring. However, it is still necessary to provide precise EV subtype classification, standardized protocols, and larger patient cohort studies for further clinical translation.

Almost all EVs seen in the blood are from blood cells, such as platelets, red blood cells, or immune cells, and a small percentage are from tissues such as the liver, lungs, or kidneys. Conventional isolation techniques cannot distinguish between EVs based on their origin, thus limiting progress in disease biomarker discovery. Thus, many pharmaceutical companies are focusing on developing a novel and robust method to isolate tissue-specific EVs from blood to address these challenges.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1920

Some of the prominent players in the EV-based Liquid Biopsy Market are:

Abcam plc
AMS Biotechnology Limited (AMSBIO)
Bio-Techne Corporation
Horiba Ltd.
Qiagen N.V.
Thermo Fisher Scientific, Inc.
Lonza Group AG
Malvern Panalytical Ltd
Revvity, Inc. (PerkinElmer, Inc.)
Takara Bio Inc.
Emerging Companies
Mursla Bio
Nanostics Inc.
Mercy BioAnalytics, Inc.
Clara Diagnostics, Inc. (Clara Biotech)
Other Prominent Players

EV-based Liquid Biopsy Market Report Scope

Report Attribute	Specifications
Market Size Value In 2022	USD 74.61 Million
Revenue Forecast In 2031	USD 349.19 Million
Growth Rate CAGR	CAGR of 18.9 % from 2023 to 2031
Quantitative Units	Representation of revenue in US$ Million and CAGR from 2023 to 2031
Historic Year	2019 to 2022
Forecast Year	2023-2031
Report Coverage	The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered	By Offering, By Workflow, By Technology, By Sample Type, By End User
Regional Scope	North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope	U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia
Competitive Landscape	Abcam plc, AMS Biotechnology Limited (AMSBIO), Bio-Techne Corporation, Horiba Ltd., Qiagen N.V., Thermo Fisher Scientific, Inc., Lonza Group AG, Malvern Panalytical Ltd, Revvity, Inc. (PerkinElmer, Inc.), Takara Bio Inc., Emerging Companies, Mursla Bio, Nanostics Inc., Mercy BioAnalytics, Inc., Clara Diagnostics, Inc. (Clara Biotech), and others.
Customization Scope	Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing and Available Payment Methods	Explore pricing alternatives that are customized to your particular study requirements.

Curious about this latest version of the report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1920

Market Dynamics:

Drivers:

The increasing number of cancer cases is surging the demand for liquid biopsy.

The EV-based liquid biopsy market is mainly driven by the high prevalence of cancer and rising public awareness about the different non-invasive treatments. As per the data provided by WCRF International (World Cancer Research Fund International), nearly 18.1 million cancer cases worldwide were reported in 2020. Thus, the high prevalence of cancer is expected to enhance the demand for EV-based liquid biopsy techniques during the forecast period.

Moreover, the increasing investments by market players in clinical trials to develop new diagnostic tests, high demand for personalized medicine, modifications in medical technologies, and growing R&D efforts in clinical oncology contribute to the market's growth.

Challenges:

However, the lack of standardized and clinically feasible EV purification & characterization protocols hinders the applicability of EV-based cancer biomarker analysis, which is expected to restrict the growth of the EV-based Liquid Biopsy Market in the coming years.

Regional Trends:

North America accounted for the maximum revenue share of the EV-based Liquid Biopsy Market in 2022. This is primarily due to the increasing prevalence of cancer in this region. In addition, growing demand for personalized therapies, increasing healthcare expenditure, and rising cancer research investments have boosted market growth. On the other hand, Asia Pacific is predicted to be the fastest-growing market over the forecast period. This is attributable to the increasing public awareness regarding liquid biopsy applications, well-established healthcare infrastructure, and rising adoption of advanced medical techniques in hospitals, clinics, and diagnostic laboratories for diagnosis.

Key developments in the market:

In May 2023, Mursla Bio discovered a new method in liquid biopsy and precision medicine to isolate tissue-specific extracellular vesicles (EVs) from the blood in addition to using a workflow to analyze their diverse multi-omics content.
In March 2019, QIAGEN launched novel liquid biopsy solutions and NGS panels with seamlessly integrated bioinformatics to support advances in cancer research.
In July 2018, Exosomics Siena S.p.A., a pioneer & world leader in exosome-based diagnostics, launched its first proprietary liquid biopsy solutions, SeleCTEV™ DNA and SortEV™ RNA, for the selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum.

Market Segments

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Offering

Kits and Assays
Instruments
Services

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Workflow

Sample Preparation
Sequencing
Data Analysis

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Technology

Isolation Technologies

Precipitation
Ultracentrifugation
Chromatography

Analysis Technologies

NGS
PCR
Flow Cytometry

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Sample Type

Blood (Plasma/Serum)
Urine
Saliva
Other Biofluids (CF - Cerebrospinal fluid)
Cell Culture

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on End User

Academic and Research Institutions
Clinical Laboratories
Pharmaceutical and Biotechnology Companies

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

North America EV-based Liquid Biopsy Market Revenue (US$ Million) by Country, 2023 to 2031

U.S.
Canada

Europe EV-based Liquid Biopsy Market Revenue (US$ Million) by Country, 2023 to 2031

Germany
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific EV-based Liquid Biopsy Market Revenue (US$ Million) by Country, 2023 to 2031

India
China
Japan
South Korea
Australia & New Zealand

Latin America EV-based Liquid Biopsy Market Revenue (US$ Million) by Country, 2023 to 2031

Brazil
Mexico
Rest of Latin America

Middle East & Africa EV-based Liquid Biopsy Market Revenue (US$ Million) by Country, 2023 to 2031

GCC Countries
South Africa
Rest of Middle East & Africa

Obtain Report Customization Details @ https://www.insightaceanalytic.com/customisation/1920

Why should buy this report:

To receive a comprehensive analysis of the prospects for the global EV-based Liquid Biopsy Market
To receive an industry overview and future trends in the global EV-based Liquid Biopsy Market
To analyze the EV-based Liquid Biopsy Market drivers and challenges
To get information on the EV-based Liquid Biopsy Market size value (US$ Mn) forecast till 2031
Major Investments, Mergers & Acquisitions in the global EV-based Liquid Biopsy Market industry

Other Related Reports Published by InsightAce Analytic:

Multi Cancer Early Detection Market

Proteomics Market

Cancer Diagnostics Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis of key market insights in a timely and cost-effective manner.

Contact Us:

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: [email protected]
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

SOURCE InsightAce Analytic Pvt. Ltd